From the Guidelines

Liposomal amphotericin B is preferred over conventional amphotericin B due to its reduced nephrotoxicity and similar efficacy.

Nephrotoxicity: Liposomal amphotericin B has been shown to have less nephrotoxic potential compared to conventional amphotericin B 1.
Efficacy: Both formulations have similar clinical and microbiological efficacy, with liposomal amphotericin B allowing for higher doses and improved antifungal effectivity 1.
Dosing: The optimal dose of liposomal amphotericin B has not been determined, but a dose of 4-6 mg/kg daily is recommended 1.
Toxicity: Conventional amphotericin B is associated with dose-limiting toxicities, including infusion-related reactions and nephrotoxicity, which are reduced with liposomal formulations 1.

Patient Selection: Liposomal amphotericin B is preferred for patients who are at high risk of nephrotoxicity or have pre-existing renal dysfunction 1.
Monitoring: Patients receiving liposomal amphotericin B should be monitored for renal function and adverse events, although the risk of nephrotoxicity is lower compared to conventional amphotericin B 1.
Alternative Agents: Other antifungal agents, such as azoles and echinocandins, may be considered as alternatives to amphotericin B formulations, depending on the specific clinical scenario and patient factors 1.

From the Research

The main differences between liposomal and conventional amphotericin B are:

Reduced toxicity: Liposomal amphotericin B has fewer infusion-related adverse events and less nephrotoxicity compared to conventional amphotericin B 2, 3, 4, 5, 6
Improved efficacy: Liposomal amphotericin B has been shown to be more effective than conventional amphotericin B in some studies, particularly in patients with disseminated histoplasmosis and AIDS 3, 6
Pharmacokinetics: Liposomal amphotericin B has nonlinear pharmacokinetics, with higher than dose-proportional increases in exposure, and is rapidly and extensively distributed after single and multiple doses 3
Indications: Liposomal amphotericin B is indicated for the treatment of documented fungal infections in patients failing conventional amphotericin B or with renal impairment, as well as for empirical therapy in febrile neutropenic patients 2, 3

Lipid composition: Liposomal amphotericin B is a unilamellar vesicle composed of amphotericin B and phospholipid 5
Mechanism of action: Liposomal amphotericin B works by binding to ergosterol in fungal cell membranes, causing an increase in membrane permeability and cell death 3, 5
Clinical efficacy: Liposomal amphotericin B has been shown to be effective in the treatment of various fungal infections, including candidiasis, aspergillosis, and histoplasmosis 3, 4, 6

Infusion-related events: Liposomal amphotericin B has fewer infusion-related adverse events compared to conventional amphotericin B 2, 3, 4, 5, 6
Nephrotoxicity: Liposomal amphotericin B has less nephrotoxicity compared to conventional amphotericin B 2, 3, 4, 5, 6
Cost: Liposomal amphotericin B is more expensive than conventional amphotericin B 2, 3